MedTrace Logo

Kadcyla In pAtients With bRAin Metastasis

NCT03203616 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-11-29

No results posted yet for this study

Summary

Women with breast cancer often develop metastases in the brain. Currently, treatment of these metastases is difficult and relies on radiotherapy or surgery which often fail. Therefore, development of new methods of treatment for breast cancer with brain metastasis is very important. T-DM1 is a drug that is already in everyday use for a specific type of breast cancer called HER2-positive breast cancer. The objective of this study is to investigate whether T-DM1 is also effective in brain metastasis and can help patients to live longer and better

Conditions

  • Metastatic HER2-positive Breast Cancer With Brain Metastasis

Interventions

DRUG

KADCYLA 160 MG Injection

Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks

Sponsors & Collaborators

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Evandro de Azambuja, MD · Jules Bordet Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-23
Primary Completion
2018-08-27
Completion
2018-08-27

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03203616 on ClinicalTrials.gov